MARKET

CYTH

CYTH

Cyclo Therapeutics Inc
NASDAQ
1.300
+0.090
+7.44%
After Hours: 1.250 -0.05 -3.85% 19:30 04/24 EDT
OPEN
1.230
PREV CLOSE
1.210
HIGH
1.310
LOW
1.220
VOLUME
21.10K
TURNOVER
0
52 WEEK HIGH
2.570
52 WEEK LOW
0.6801
MARKET CAP
37.33M
P/E (TTM)
-1.0584
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at CYTH last week (0415-0419)?
Weekly Report · 2d ago
Cyclo Therapeutics Initiated at Buy by Ascendiant Capital
Dow Jones · 2d ago
Cyclo Therapeutics Price Target Announced at $2.60/Share by Ascendiant Capital
Dow Jones · 2d ago
Ascendiant Capital Initiates Coverage On Cyclo Therapeutics with Buy Rating, Announces Price Target of $2.6
Benzinga · 2d ago
Analysts Offer Insights on Healthcare Companies: Cyclo Therapeutics (CYTH), CytomX Therapeutics (CTMX) and Pacific Biosciences (PACB)
TipRanks · 2d ago
12 Health Care Stocks Moving In Thursday's After-Market Session
Bio-Path Hldgs (NASDAQ:BPTH) stock moved upwards by 9.0% to $4.58 during Thursday's after-market session. Biora Therapeutics, Mustang Bio and China SXT Pharmaceuticals were among the top gainers. Virpax Pharmaceuticals stock decreased by 18.2% during the session.
Benzinga · 6d ago
Weekly Report: what happened at CYTH last week (0408-0412)?
Weekly Report · 04/15 11:55
Weekly Report: what happened at CYTH last week (0401-0405)?
Weekly Report · 04/08 12:02
More
About CYTH
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing transformative therapies for rare and neurological diseases with limited treatment options. The Company’s Trappsol Cyclo is a proprietary formulation of hydroxypropyl beta cyclodextrin. It is an orphan drug designated product in the United States and Europe, and is the subject of four formal clinical trials for Niemann-Pick Disease Type C (NPC) disease. NPC is a rare and fatal autosomal recessive genetic disease resulting in disrupted cholesterol metabolism that impacts the brain, lungs, liver, spleen, and other organs. The Company is also engaged in conducting a Phase 2b clinical trial using Trappsol Cyclo intravenously in early Alzheimer’s disease (NCT05607615) based on encouraging data from an Expanded Access program for Alzheimer’s disease (NCT03624842).

Webull offers Cyclo Therapeutics Inc stock information, including NASDAQ: CYTH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYTH stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CYTH stock methods without spending real money on the virtual paper trading platform.